Kathryn Hassell
Concepts (536)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 49 | 2026 | 322 | 6.830 |
Why?
| | Water Pollutants, Chemical | 13 | 2022 | 227 | 2.090 |
Why?
| | Antiphospholipid Syndrome | 5 | 2023 | 37 | 1.680 |
Why?
| | Migraine Disorders | 2 | 2023 | 109 | 1.240 |
Why?
| | Perciformes | 5 | 2018 | 20 | 1.100 |
Why?
| | Anticoagulants | 8 | 2021 | 743 | 1.090 |
Why?
| | Heparin | 5 | 2011 | 246 | 1.060 |
Why?
| | Thrombocytopenia | 5 | 2014 | 205 | 1.050 |
Why?
| | Hypertension, Pulmonary | 14 | 2026 | 1957 | 1.040 |
Why?
| | Antibodies, Antiphospholipid | 4 | 2023 | 29 | 0.990 |
Why?
| | Fishes | 4 | 2021 | 111 | 0.980 |
Why?
| | Hemoglobins | 9 | 2026 | 384 | 0.820 |
Why?
| | Estrogens | 3 | 2016 | 364 | 0.770 |
Why?
| | Hydroxyurea | 5 | 2016 | 35 | 0.750 |
Why?
| | Hemopexin | 4 | 2025 | 40 | 0.720 |
Why?
| | Pyridones | 2 | 2021 | 210 | 0.680 |
Why?
| | Disorders of Sex Development | 2 | 2018 | 40 | 0.660 |
Why?
| | Blood Transfusion | 7 | 2015 | 393 | 0.650 |
Why?
| | Hirudins | 4 | 2011 | 52 | 0.640 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 240 | 0.620 |
Why?
| | Testis | 2 | 2018 | 157 | 0.620 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 302 | 0.610 |
Why?
| | Caprylates | 1 | 2020 | 21 | 0.610 |
Why?
| | Alkanesulfonic Acids | 1 | 2020 | 37 | 0.600 |
Why?
| | Environmental Monitoring | 8 | 2025 | 346 | 0.590 |
Why?
| | Pyrazoles | 2 | 2021 | 516 | 0.580 |
Why?
| | Oocytes | 2 | 2021 | 186 | 0.550 |
Why?
| | Fluorocarbons | 1 | 2020 | 122 | 0.550 |
Why?
| | Quality of Life | 6 | 2017 | 3187 | 0.530 |
Why?
| | Haptoglobins | 4 | 2026 | 71 | 0.520 |
Why?
| | Neonatal Screening | 3 | 2020 | 185 | 0.510 |
Why?
| | Cyprinidae | 1 | 2016 | 22 | 0.470 |
Why?
| | Australia | 10 | 2022 | 291 | 0.470 |
Why?
| | Pain | 5 | 2023 | 787 | 0.470 |
Why?
| | beta-Thalassemia | 2 | 2025 | 40 | 0.400 |
Why?
| | Pain Measurement | 3 | 2017 | 567 | 0.400 |
Why?
| | Embryo, Nonmammalian | 2 | 2019 | 171 | 0.400 |
Why?
| | Hypoxia | 5 | 2026 | 1209 | 0.400 |
Why?
| | Health Status Indicators | 1 | 2014 | 166 | 0.390 |
Why?
| | Surveys and Questionnaires | 4 | 2017 | 6050 | 0.390 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 128 | 0.390 |
Why?
| | Humans | 79 | 2026 | 145625 | 0.370 |
Why?
| | Tricuspid Valve Insufficiency | 3 | 2011 | 23 | 0.370 |
Why?
| | Vascular Remodeling | 3 | 2026 | 208 | 0.360 |
Why?
| | Adult | 41 | 2025 | 40821 | 0.360 |
Why?
| | Peptide Fragments | 4 | 2014 | 693 | 0.350 |
Why?
| | Sewage | 2 | 2025 | 30 | 0.340 |
Why?
| | Antithrombins | 2 | 2011 | 70 | 0.340 |
Why?
| | Animals | 31 | 2026 | 38030 | 0.330 |
Why?
| | Thrombosis | 4 | 2021 | 397 | 0.330 |
Why?
| | Empirical Research | 1 | 2011 | 21 | 0.330 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 727 | 0.320 |
Why?
| | Nomograms | 1 | 2011 | 59 | 0.320 |
Why?
| | Male | 48 | 2025 | 73014 | 0.310 |
Why?
| | Censuses | 1 | 2010 | 33 | 0.310 |
Why?
| | Endocrine Disruptors | 3 | 2016 | 42 | 0.300 |
Why?
| | Rivaroxaban | 2 | 2025 | 270 | 0.290 |
Why?
| | Vitellogenins | 3 | 2016 | 11 | 0.290 |
Why?
| | Female | 43 | 2025 | 79080 | 0.290 |
Why?
| | Venous Thromboembolism | 2 | 2025 | 330 | 0.280 |
Why?
| | Heme | 3 | 2025 | 90 | 0.280 |
Why?
| | Health Priorities | 1 | 2009 | 45 | 0.280 |
Why?
| | Thrombophilia | 3 | 2007 | 89 | 0.280 |
Why?
| | Anemia, Hemolytic | 2 | 2026 | 21 | 0.270 |
Why?
| | Young Adult | 18 | 2025 | 14240 | 0.270 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2008 | 13 | 0.270 |
Why?
| | Estuaries | 2 | 2021 | 2 | 0.260 |
Why?
| | Iron | 4 | 2025 | 359 | 0.260 |
Why?
| | Gonads | 2 | 2018 | 23 | 0.260 |
Why?
| | Self Care | 1 | 2010 | 396 | 0.260 |
Why?
| | Nitric Oxide | 2 | 2018 | 883 | 0.260 |
Why?
| | Biodiversity | 2 | 2021 | 314 | 0.260 |
Why?
| | Population Surveillance | 2 | 2010 | 477 | 0.260 |
Why?
| | Heart Septal Defects, Atrial | 2 | 2005 | 58 | 0.250 |
Why?
| | Stroke | 3 | 2021 | 1283 | 0.250 |
Why?
| | Sickle Cell Trait | 2 | 2018 | 15 | 0.250 |
Why?
| | Macrophages | 3 | 2026 | 1530 | 0.250 |
Why?
| | Fresh Water | 3 | 2020 | 53 | 0.250 |
Why?
| | Kinetics | 2 | 2020 | 1553 | 0.240 |
Why?
| | Middle Aged | 25 | 2025 | 36359 | 0.240 |
Why?
| | Hospitalists | 1 | 2011 | 288 | 0.240 |
Why?
| | Phospholipids | 1 | 2008 | 215 | 0.240 |
Why?
| | Environmental Pollutants | 2 | 2019 | 142 | 0.240 |
Why?
| | Insecta | 1 | 2006 | 73 | 0.230 |
Why?
| | Estradiol | 4 | 2016 | 517 | 0.230 |
Why?
| | Acoustics | 1 | 2026 | 45 | 0.230 |
Why?
| | Lung | 5 | 2026 | 4119 | 0.230 |
Why?
| | Fats | 1 | 2025 | 13 | 0.230 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 24 | 0.230 |
Why?
| | Patient Education as Topic | 1 | 2010 | 769 | 0.220 |
Why?
| | Cation Transport Proteins | 1 | 2026 | 120 | 0.220 |
Why?
| | Adolescent | 20 | 2025 | 22451 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 700 | 0.210 |
Why?
| | Estrone | 2 | 2016 | 41 | 0.210 |
Why?
| | Spleen | 2 | 2025 | 503 | 0.210 |
Why?
| | Health Services Accessibility | 3 | 2016 | 1101 | 0.210 |
Why?
| | Hospitalization | 4 | 2025 | 2468 | 0.210 |
Why?
| | Cadmium | 2 | 2021 | 68 | 0.190 |
Why?
| | Hypertrichosis | 1 | 2023 | 9 | 0.190 |
Why?
| | Hemoglobinopathies | 1 | 2023 | 6 | 0.190 |
Why?
| | Acromegaly | 1 | 2023 | 17 | 0.190 |
Why?
| | Headache | 2 | 2023 | 149 | 0.190 |
Why?
| | Antisickling Agents | 2 | 2016 | 8 | 0.190 |
Why?
| | Limb Deformities, Congenital | 1 | 2023 | 21 | 0.190 |
Why?
| | Factor Xa Inhibitors | 1 | 2025 | 194 | 0.190 |
Why?
| | Wetlands | 2 | 2022 | 33 | 0.190 |
Why?
| | Hemostasis | 2 | 2007 | 100 | 0.190 |
Why?
| | Bays | 3 | 2017 | 7 | 0.180 |
Why?
| | Child | 20 | 2024 | 22638 | 0.180 |
Why?
| | Volatile Organic Compounds | 1 | 2023 | 48 | 0.180 |
Why?
| | Psychometrics | 3 | 2016 | 708 | 0.180 |
Why?
| | Pesticides | 1 | 2022 | 59 | 0.180 |
Why?
| | Mass Screening | 1 | 2011 | 1300 | 0.180 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2910 | 0.180 |
Why?
| | Recombinant Proteins | 4 | 2011 | 1361 | 0.180 |
Why?
| | Arginine | 2 | 2015 | 263 | 0.170 |
Why?
| | Hemolysis | 4 | 2021 | 242 | 0.170 |
Why?
| | Metallothionein | 1 | 2021 | 24 | 0.170 |
Why?
| | Arterial Occlusive Diseases | 1 | 2021 | 87 | 0.160 |
Why?
| | alpha-Thalassemia | 1 | 2020 | 5 | 0.160 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2021 | 82 | 0.160 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.160 |
Why?
| | Acute Pain | 1 | 2021 | 58 | 0.160 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2021 | 71 | 0.160 |
Why?
| | Fertility Preservation | 1 | 2021 | 57 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 520 | 0.150 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 175 | 0.150 |
Why?
| | Ecotoxicology | 1 | 2019 | 3 | 0.150 |
Why?
| | Partial Thromboplastin Time | 2 | 2011 | 53 | 0.150 |
Why?
| | Disease Models, Animal | 7 | 2026 | 4565 | 0.150 |
Why?
| | Infertility, Female | 1 | 2021 | 124 | 0.150 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2016 | 29 | 0.150 |
Why?
| | Clove Oil | 1 | 2019 | 1 | 0.150 |
Why?
| | Eugenol | 1 | 2019 | 4 | 0.150 |
Why?
| | Iron Chelating Agents | 2 | 2011 | 17 | 0.150 |
Why?
| | Cyprinodontiformes | 1 | 2019 | 5 | 0.150 |
Why?
| | Multiple Organ Failure | 2 | 2005 | 122 | 0.150 |
Why?
| | Aged | 11 | 2025 | 26251 | 0.150 |
Why?
| | Iron Overload | 2 | 2011 | 19 | 0.150 |
Why?
| | Benzoates | 2 | 2011 | 48 | 0.150 |
Why?
| | Unrelated Donors | 1 | 2019 | 39 | 0.140 |
Why?
| | Exercise Tolerance | 2 | 2011 | 288 | 0.140 |
Why?
| | Liver | 3 | 2025 | 1859 | 0.140 |
Why?
| | Prospective Studies | 9 | 2025 | 8087 | 0.140 |
Why?
| | Plastics | 1 | 2019 | 50 | 0.140 |
Why?
| | Altitude | 3 | 2018 | 469 | 0.140 |
Why?
| | Hemorrhage | 2 | 2021 | 824 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2017 | 3396 | 0.140 |
Why?
| | Signal Transduction | 2 | 2013 | 5234 | 0.130 |
Why?
| | Anesthetics | 1 | 2019 | 100 | 0.130 |
Why?
| | Europe | 2 | 2016 | 420 | 0.130 |
Why?
| | Triazoles | 2 | 2011 | 190 | 0.130 |
Why?
| | Practice Guidelines as Topic | 3 | 2015 | 1581 | 0.130 |
Why?
| | Bone Marrow Transplantation | 1 | 2019 | 298 | 0.130 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 271 | 0.130 |
Why?
| | Aspirin | 1 | 2021 | 404 | 0.130 |
Why?
| | Physical Exertion | 1 | 2018 | 204 | 0.130 |
Why?
| | Lipids | 2 | 2023 | 715 | 0.130 |
Why?
| | Lipoproteins | 1 | 2018 | 165 | 0.130 |
Why?
| | Factor Analysis, Statistical | 2 | 2016 | 295 | 0.130 |
Why?
| | Climate Change | 1 | 2019 | 184 | 0.120 |
Why?
| | Pulmonary Artery | 4 | 2019 | 1116 | 0.120 |
Why?
| | Prevalence | 4 | 2024 | 2852 | 0.120 |
Why?
| | Platelet Factor 4 | 2 | 2008 | 36 | 0.120 |
Why?
| | Cohort Studies | 7 | 2018 | 6045 | 0.120 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 37 | 0.120 |
Why?
| | Biomarkers | 6 | 2026 | 4329 | 0.120 |
Why?
| | Zinc | 1 | 2020 | 310 | 0.120 |
Why?
| | Treatment Outcome | 6 | 2025 | 11744 | 0.120 |
Why?
| | Osmeriformes | 1 | 2016 | 1 | 0.120 |
Why?
| | Carps | 1 | 2016 | 5 | 0.120 |
Why?
| | Phenylketonurias | 1 | 2016 | 15 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 341 | 0.120 |
Why?
| | Asia | 1 | 2016 | 69 | 0.120 |
Why?
| | United States | 11 | 2023 | 16041 | 0.120 |
Why?
| | Principal Component Analysis | 2 | 2016 | 192 | 0.120 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 280 | 0.120 |
Why?
| | Olfactory Perception | 1 | 2016 | 18 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2019 | 639 | 0.120 |
Why?
| | Metals, Heavy | 1 | 2016 | 31 | 0.120 |
Why?
| | Rivers | 1 | 2016 | 62 | 0.120 |
Why?
| | Employment | 2 | 2014 | 180 | 0.120 |
Why?
| | Trace Elements | 1 | 2016 | 52 | 0.110 |
Why?
| | Erythrocyte Transfusion | 2 | 2015 | 225 | 0.110 |
Why?
| | Mice | 8 | 2026 | 18266 | 0.110 |
Why?
| | Anesthesia | 1 | 2019 | 257 | 0.110 |
Why?
| | Thalassemia | 1 | 2015 | 6 | 0.110 |
Why?
| | Infant, Newborn | 5 | 2024 | 6449 | 0.110 |
Why?
| | Copper | 1 | 2016 | 122 | 0.110 |
Why?
| | North America | 1 | 2016 | 299 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 992 | 0.110 |
Why?
| | Lung Diseases | 2 | 2019 | 787 | 0.110 |
Why?
| | Splenic Infarction | 1 | 2014 | 1 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2021 | 17291 | 0.110 |
Why?
| | Protein S Deficiency | 1 | 1994 | 8 | 0.110 |
Why?
| | Fatigue | 1 | 2017 | 362 | 0.110 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.100 |
Why?
| | Zebrafish | 1 | 2019 | 533 | 0.100 |
Why?
| | Blood Component Removal | 1 | 2014 | 26 | 0.100 |
Why?
| | Complement Inactivator Proteins | 1 | 1994 | 39 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 191 | 0.100 |
Why?
| | Quality of Health Care | 2 | 2016 | 692 | 0.100 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 116 | 0.100 |
Why?
| | Leg Ulcer | 1 | 2013 | 4 | 0.100 |
Why?
| | Thromboembolism | 1 | 2014 | 129 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 105 | 0.100 |
Why?
| | Larva | 2 | 2019 | 242 | 0.100 |
Why?
| | Blood Flow Velocity | 2 | 2014 | 419 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 6021 | 0.100 |
Why?
| | Ethinyl Estradiol | 1 | 2012 | 16 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 845 | 0.090 |
Why?
| | Thrombin | 2 | 2023 | 174 | 0.090 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 119 | 0.090 |
Why?
| | Venous Thrombosis | 2 | 2005 | 195 | 0.090 |
Why?
| | Sex Factors | 3 | 2019 | 2101 | 0.090 |
Why?
| | Racism | 1 | 2014 | 147 | 0.090 |
Why?
| | Societies, Medical | 1 | 2017 | 901 | 0.090 |
Why?
| | Testosterone | 1 | 2016 | 419 | 0.090 |
Why?
| | Neoplasms | 2 | 2021 | 2944 | 0.090 |
Why?
| | Preoperative Care | 2 | 2005 | 375 | 0.090 |
Why?
| | Chronic Pain | 1 | 2017 | 302 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 502 | 0.090 |
Why?
| | Prostheses and Implants | 2 | 2021 | 137 | 0.090 |
Why?
| | Hemoglobin SC Disease | 3 | 1998 | 14 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 952 | 0.090 |
Why?
| | Pharmacists | 1 | 2014 | 260 | 0.090 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 1158 | 0.080 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 533 | 0.080 |
Why?
| | Child, Preschool | 10 | 2024 | 11888 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2016 | 627 | 0.080 |
Why?
| | Mortality | 2 | 2012 | 375 | 0.080 |
Why?
| | Creatinine | 2 | 2014 | 511 | 0.080 |
Why?
| | Pipecolic Acids | 1 | 2011 | 26 | 0.080 |
Why?
| | Transfusion Reaction | 1 | 2011 | 61 | 0.080 |
Why?
| | Hemofiltration | 1 | 2010 | 24 | 0.080 |
Why?
| | Sulfones | 1 | 2011 | 127 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2013 | 627 | 0.080 |
Why?
| | Disease Progression | 4 | 2023 | 2857 | 0.070 |
Why?
| | Awareness | 1 | 2010 | 113 | 0.070 |
Why?
| | Disease Management | 2 | 2011 | 649 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2018 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2011 | 326 | 0.070 |
Why?
| | Oxidative Stress | 2 | 2026 | 1367 | 0.070 |
Why?
| | Piperazines | 1 | 2011 | 367 | 0.070 |
Why?
| | Career Choice | 1 | 2010 | 235 | 0.070 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 83 | 0.070 |
Why?
| | United Kingdom | 3 | 2014 | 376 | 0.070 |
Why?
| | Echocardiography | 1 | 2011 | 645 | 0.070 |
Why?
| | Drug Utilization Review | 1 | 2008 | 60 | 0.070 |
Why?
| | Anaerobiosis | 1 | 2008 | 65 | 0.070 |
Why?
| | Seawater | 1 | 2008 | 33 | 0.070 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 391 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 154 | 0.070 |
Why?
| | Pregnancy | 3 | 2005 | 7217 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 1075 | 0.070 |
Why?
| | Software | 1 | 2013 | 673 | 0.070 |
Why?
| | Body Size | 1 | 2008 | 91 | 0.060 |
Why?
| | Cost of Illness | 1 | 2010 | 322 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8351 | 0.060 |
Why?
| | Community Participation | 1 | 2009 | 128 | 0.060 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 122 | 0.060 |
Why?
| | Depression | 1 | 2017 | 1566 | 0.060 |
Why?
| | Lipid Peroxidation | 2 | 2018 | 168 | 0.060 |
Why?
| | Metabolomics | 1 | 2013 | 737 | 0.060 |
Why?
| | Endothelial Cells | 1 | 2013 | 876 | 0.060 |
Why?
| | Deferoxamine | 1 | 2007 | 27 | 0.060 |
Why?
| | Proteomics | 2 | 2025 | 1202 | 0.060 |
Why?
| | Chironomidae | 1 | 2006 | 1 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2023 | 2064 | 0.060 |
Why?
| | Sulfonamides | 1 | 2011 | 592 | 0.060 |
Why?
| | Age Factors | 2 | 2014 | 3321 | 0.060 |
Why?
| | Environmental Exposure | 3 | 2019 | 578 | 0.060 |
Why?
| | Rhabdomyolysis | 2 | 2018 | 24 | 0.060 |
Why?
| | Acute Kidney Injury | 2 | 2010 | 861 | 0.060 |
Why?
| | Urbanization | 2 | 2016 | 28 | 0.060 |
Why?
| | Algorithms | 1 | 2014 | 1843 | 0.060 |
Why?
| | Social Support | 1 | 2010 | 644 | 0.060 |
Why?
| | Registries | 2 | 2023 | 2382 | 0.060 |
Why?
| | Body Weight | 2 | 2021 | 964 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 138 | 0.060 |
Why?
| | Coronary Angiography | 1 | 2008 | 325 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 7079 | 0.060 |
Why?
| | Fibrinolysis | 2 | 1998 | 161 | 0.060 |
Why?
| | Ecosystem | 2 | 2021 | 483 | 0.060 |
Why?
| | Oils | 1 | 2025 | 22 | 0.060 |
Why?
| | Erythrocytes | 2 | 2026 | 749 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2020 | 538 | 0.060 |
Why?
| | Species Specificity | 1 | 2006 | 542 | 0.060 |
Why?
| | Dermatan Sulfate | 1 | 2005 | 4 | 0.060 |
Why?
| | Captopril | 1 | 2005 | 11 | 0.050 |
Why?
| | Factor V | 1 | 2005 | 26 | 0.050 |
Why?
| | Waste Disposal, Fluid | 1 | 2025 | 52 | 0.050 |
Why?
| | Chondroitin Sulfates | 1 | 2005 | 35 | 0.050 |
Why?
| | Survival Analysis | 1 | 2008 | 1372 | 0.050 |
Why?
| | Angina, Unstable | 1 | 2005 | 83 | 0.050 |
Why?
| | Heme Oxygenase-1 | 1 | 2025 | 76 | 0.050 |
Why?
| | Risk | 2 | 2005 | 917 | 0.050 |
Why?
| | Polysaccharides | 1 | 2005 | 88 | 0.050 |
Why?
| | Standard of Care | 1 | 2025 | 81 | 0.050 |
Why?
| | Infant Mortality | 1 | 2005 | 127 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2024 | 84 | 0.050 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2005 | 83 | 0.050 |
Why?
| | Chest Pain | 1 | 2005 | 100 | 0.050 |
Why?
| | Aerosols | 1 | 2025 | 146 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2008 | 899 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2357 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 403 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 99 | 0.050 |
Why?
| | Alabama | 1 | 2023 | 33 | 0.050 |
Why?
| | Acute Disease | 2 | 2019 | 1033 | 0.050 |
Why?
| | Drug Combinations | 1 | 2005 | 399 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 2 | 2013 | 1370 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5397 | 0.050 |
Why?
| | Syndrome | 2 | 2014 | 377 | 0.050 |
Why?
| | Simazine | 1 | 2022 | 2 | 0.050 |
Why?
| | ortho-Aminobenzoates | 1 | 2022 | 8 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 341 | 0.050 |
Why?
| | Risk Factors | 5 | 2018 | 10840 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2025 | 300 | 0.050 |
Why?
| | E-Selectin | 1 | 2023 | 61 | 0.050 |
Why?
| | Oxygen | 1 | 2008 | 996 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 172 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 395 | 0.050 |
Why?
| | Medical Records | 1 | 2023 | 190 | 0.050 |
Why?
| | Glycolipids | 1 | 2023 | 53 | 0.050 |
Why?
| | Agriculture | 1 | 2022 | 94 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 751 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2025 | 558 | 0.040 |
Why?
| | P-Selectin | 1 | 2021 | 29 | 0.040 |
Why?
| | Data Collection | 1 | 2024 | 647 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2009 | 728 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 566 | 0.040 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 1098 | 0.040 |
Why?
| | Colorado | 3 | 2024 | 4588 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2910 | 0.040 |
Why?
| | Blood Pressure | 3 | 2018 | 1761 | 0.040 |
Why?
| | Dietary Exposure | 1 | 2021 | 9 | 0.040 |
Why?
| | Vitrification | 1 | 2021 | 7 | 0.040 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2021 | 6 | 0.040 |
Why?
| | Oogenesis | 1 | 2021 | 20 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2021 | 20 | 0.040 |
Why?
| | Phylogeography | 1 | 2021 | 51 | 0.040 |
Why?
| | Ovulation Induction | 1 | 2021 | 68 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1531 | 0.040 |
Why?
| | Monocytes | 1 | 2023 | 538 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2021 | 62 | 0.040 |
Why?
| | von Willebrand Factor | 2 | 1998 | 84 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 585 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2021 | 206 | 0.040 |
Why?
| | Australasia | 1 | 2019 | 2 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2004 | 569 | 0.040 |
Why?
| | Metals | 1 | 2021 | 137 | 0.040 |
Why?
| | Cryopreservation | 1 | 2021 | 115 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2021 | 265 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2021 | 215 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 78 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3633 | 0.040 |
Why?
| | HIV Infections | 1 | 1994 | 3210 | 0.030 |
Why?
| | Cell Line | 2 | 2015 | 2809 | 0.030 |
Why?
| | Rats | 2 | 2019 | 5574 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2019 | 334 | 0.030 |
Why?
| | Proteinuria | 1 | 2018 | 103 | 0.030 |
Why?
| | Endothelins | 1 | 2018 | 61 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2018 | 159 | 0.030 |
Why?
| | Thrombomodulin | 1 | 1998 | 15 | 0.030 |
Why?
| | Allografts | 1 | 2019 | 148 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2005 | 1754 | 0.030 |
Why?
| | Body Height | 1 | 2018 | 202 | 0.030 |
Why?
| | Victoria | 1 | 2017 | 22 | 0.030 |
Why?
| | Public Health Practice | 1 | 2017 | 63 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 782 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 777 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 169 | 0.030 |
Why?
| | Fish Proteins | 1 | 2016 | 13 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2016 | 16 | 0.030 |
Why?
| | Bile | 1 | 2016 | 26 | 0.030 |
Why?
| | Public-Private Sector Partnerships | 1 | 2017 | 44 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1021 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 154 | 0.030 |
Why?
| | Pilot Projects | 2 | 2016 | 1878 | 0.030 |
Why?
| | Polychlorinated Biphenyls | 1 | 2016 | 11 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1062 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 337 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 207 | 0.030 |
Why?
| | Community Health Services | 1 | 2017 | 229 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 5875 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 71 | 0.030 |
Why?
| | Odorants | 1 | 2016 | 114 | 0.030 |
Why?
| | Mononuclear Phagocyte System | 1 | 1995 | 10 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 1995 | 20 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 1995 | 14 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2013 | 2783 | 0.030 |
Why?
| | Arginase | 1 | 2015 | 26 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 297 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 3917 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 2016 | 118 | 0.030 |
Why?
| | Vitamin B 6 Deficiency | 1 | 1994 | 6 | 0.030 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.030 |
Why?
| | Amino Acids, Sulfur | 1 | 1994 | 8 | 0.030 |
Why?
| | Cysteic Acid | 1 | 1994 | 1 | 0.030 |
Why?
| | beta 2-Glycoprotein I | 1 | 1994 | 5 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 196 | 0.030 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1994 | 6 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2014 | 56 | 0.030 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1994 | 7 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 132 | 0.030 |
Why?
| | Blood Coagulation | 1 | 1996 | 267 | 0.030 |
Why?
| | Hematocrit | 1 | 2014 | 108 | 0.030 |
Why?
| | Blood Platelets | 1 | 1998 | 380 | 0.030 |
Why?
| | Interview, Psychological | 1 | 2014 | 93 | 0.030 |
Why?
| | Folic Acid Deficiency | 1 | 1994 | 49 | 0.030 |
Why?
| | Automation | 1 | 2014 | 104 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 117 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 399 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 69 | 0.030 |
Why?
| | Penicillins | 1 | 2014 | 65 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2015 | 151 | 0.030 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1994 | 81 | 0.030 |
Why?
| | Pharmaceutical Services | 1 | 2014 | 76 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 449 | 0.030 |
Why?
| | Hematologic Tests | 1 | 1994 | 22 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2078 | 0.030 |
Why?
| | Homocysteine | 1 | 1994 | 152 | 0.030 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 110 | 0.020 |
Why?
| | Smegmamorpha | 1 | 2013 | 6 | 0.020 |
Why?
| | DNA Damage | 1 | 2016 | 437 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2015 | 365 | 0.020 |
Why?
| | Ownership | 1 | 2014 | 115 | 0.020 |
Why?
| | Mood Disorders | 1 | 2014 | 129 | 0.020 |
Why?
| | Carrier Proteins | 2 | 1995 | 728 | 0.020 |
Why?
| | Catalase | 1 | 2013 | 133 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 88 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2014 | 148 | 0.020 |
Why?
| | Personnel Selection | 1 | 2014 | 90 | 0.020 |
Why?
| | Folic Acid | 1 | 1995 | 197 | 0.020 |
Why?
| | Hemoglobin, Sickle | 1 | 2013 | 20 | 0.020 |
Why?
| | Professional Role | 1 | 2014 | 171 | 0.020 |
Why?
| | Permeability | 1 | 2013 | 166 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 133 | 0.020 |
Why?
| | Liver Failure, Acute | 1 | 1994 | 70 | 0.020 |
Why?
| | Brain Diseases | 1 | 1994 | 157 | 0.020 |
Why?
| | Cysteine | 1 | 1994 | 210 | 0.020 |
Why?
| | Methylamines | 1 | 2013 | 39 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2014 | 279 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 519 | 0.020 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 33 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 371 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 530 | 0.020 |
Why?
| | Minority Groups | 1 | 2014 | 285 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 782 | 0.020 |
Why?
| | Glycoproteins | 1 | 1994 | 355 | 0.020 |
Why?
| | Social Behavior | 1 | 2014 | 279 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2015 | 251 | 0.020 |
Why?
| | Choline | 1 | 2013 | 134 | 0.020 |
Why?
| | Perioperative Care | 1 | 2014 | 229 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 959 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 377 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 307 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 73 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 277 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 299 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2008 | 3930 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2016 | 595 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2011 | 60 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 822 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2915 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 196 | 0.020 |
Why?
| | Public Health | 1 | 2016 | 573 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 194 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 341 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1318 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 840 | 0.020 |
Why?
| | Hemodynamics | 2 | 2011 | 1114 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1994 | 330 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2018 | 956 | 0.020 |
Why?
| | Purines | 1 | 2011 | 188 | 0.020 |
Why?
| | Communication | 1 | 2016 | 979 | 0.020 |
Why?
| | NF-kappa B | 1 | 2013 | 674 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3121 | 0.020 |
Why?
| | Metabolome | 1 | 2013 | 390 | 0.020 |
Why?
| | Walking | 1 | 2014 | 544 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2497 | 0.020 |
Why?
| | Pediatrics | 1 | 2017 | 1122 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2533 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2011 | 220 | 0.020 |
Why?
| | Pneumonia | 1 | 2015 | 633 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1481 | 0.020 |
Why?
| | Sepsis | 1 | 1995 | 668 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1461 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 634 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1866 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1652 | 0.020 |
Why?
| | Chelation Therapy | 1 | 2007 | 10 | 0.020 |
Why?
| | Infant | 3 | 2014 | 10093 | 0.020 |
Why?
| | Calcinosis | 1 | 2008 | 231 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 265 | 0.010 |
Why?
| | Health Personnel | 1 | 2013 | 750 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2007 | 151 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2218 | 0.010 |
Why?
| | Health Services | 1 | 2007 | 112 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2097 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2018 | 2962 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1795 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1758 | 0.010 |
Why?
| | Mental Disorders | 1 | 1994 | 1133 | 0.010 |
Why?
| | Program Development | 1 | 2007 | 365 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1995 | 124 | 0.010 |
Why?
| | Isotope Labeling | 2 | 1995 | 81 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 867 | 0.010 |
Why?
| | Critical Illness | 1 | 2010 | 905 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2007 | 560 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2112 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 399 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2007 | 878 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2008 | 1247 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2008 | 1212 | 0.010 |
Why?
| | Delivery of Health Care | 1 | 2007 | 942 | 0.010 |
Why?
| | Physicians | 1 | 2008 | 954 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1996 | 103 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 207 | 0.010 |
Why?
| | Folate Receptors, GPI-Anchored | 1 | 1995 | 5 | 0.010 |
Why?
| | 4-Aminobenzoic Acid | 1 | 1995 | 8 | 0.010 |
Why?
| | Vacuoles | 1 | 1995 | 36 | 0.010 |
Why?
| | Lactobacillus | 1 | 1995 | 28 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1995 | 116 | 0.010 |
Why?
| | Reference Standards | 1 | 1995 | 176 | 0.010 |
Why?
| | Carbon Isotopes | 1 | 1995 | 143 | 0.010 |
Why?
| | Aspartic Acid | 1 | 1994 | 88 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1994 | 84 | 0.010 |
Why?
| | Deuterium | 1 | 1994 | 101 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1995 | 339 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 787 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1994 | 233 | 0.010 |
Why?
| | Cattle | 1 | 1995 | 938 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1992 | 0.000 |
Why?
| | Brain | 1 | 1994 | 2981 | 0.000 |
Why?
|
|
Hassell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|